Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Exclusive: WHO-backed vaccine hub for Africa to copy Moderna COVID-19 shot

Stock MarketsSep 15, 2021 02:16AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: Vials of coronavirus disease (COVID-19) vaccines of Pfizer-BioNTech and Moderna are seen in the town of Ricany near Prague, Czech Republic, February 25, 2021. REUTERS/David W Cerny/File Photo

By Wendell Roelf

CAPE TOWN (Reuters) - Efforts to develop an African base for COVID-19 vaccine production will focus on trying to replicate Moderna (NASDAQ:MRNA)'s shot, but a lack of progress in talks with the U.S. company mean the project will take time, a senior WHO official told Reuters.

The drive to produce vaccines in Africa is designed to help more developing countries access COVID-19 shots after rich nations bought up most of this year's supply.

Moderna said last October it would not enforce patents related to its shot during the pandemic, raising hopes that other companies might be able to copy it and help boost COVID-19 vaccine production.

In practice, though, it is hard to replicate a vaccine without the information on how it is made, and the World Health Organization-backed tech transfer hub in South Africa - set up in June to give poorer nations the know-how to produce COVID-19 vaccines - has so far not reached a deal with the company.

"The talks have not yielded any results," Martin Friede, WHO Initiative for Vaccine Research coodinator, told Reuters.

Moderna did not respond to a request for comment.

The case highlights the challenges faced by the WHO as it battles to expand vaccine production to help address the glaring inequalities between rich and poor nations in the pandemic.

More than three quarters of the 5.5 billion COVID-19 shots administered worldwide have gone to high and upper-middle income countries, which make up just over a third of the world's population.

Currently only 3% of Africa is vaccinated, the African Union's top health official said last week, compared with more than half of the United States and three quarters of Spain.

Friede said Moderna's vaccine had been chosen as an abundance of public information and its pledge not to enforce patents made the shot slightly easier to copy than some rivals.

"We have to make a choice now. The deadline is upon us; time to start ordering chemicals. We've chosen Moderna," he said.

But even if the hub manages without Moderna's help, it could take more than a year to get a distributable vaccine as clinical trials would only begin in the latter half of 2022, he added.

TUSSLE OVER WAIVERS

In May, the United States said it would support waiving intellectual property rights for COVID-19 vaccines in order to help speed an end to the pandemic.

But the idea has faced opposition from pharmaceutical firms, which argue they need to oversee any technology transfer due to the complexity of the manufacturing process.

Pfizer (NYSE:PFE) and its partner BioNTech separately struck a deal in July for South Africa's Biovac to help make around 100 million doses a year of their COVID-19 vaccine for Africa. Their shot, like Moderna's, uses so-called mRNA technology.

However, the deal is to "fill and finish" the vaccine, the final stages of production where the product is put into vials, sealed and packaged for shipping. It does not cover the complicated process of mRNA production, which Pfizer and BioNTech will do at their European plants.

Neither responded to requests for comment.

The WHO has been trying to persuade Moderna and Pfizer-BioNTech to join forces with its African tech transfer hub.

But COVID-19 vaccine makers have warned that non-authorised producers would compete for vital raw materials and production gear that the established players - most of which have earned huge profits from vaccination - rely on.

Hub consortium partner Afrigen Biologics will produce the initial batch of doses, before transferring the skills and technology to local manufacturing partner, Biovac Institute - both are Cape Town-based - which will mass produce the vaccines.

"This is not something that we are asking industry to give us for free," Friede said about talks with the companies for access to information, adding that royalties, territorial limitations and other constraints could be built into a deal.

Healthcare analysts doubt the plan can be mobilised quickly.

"There are many steps which will require lots of iterations before they can be ready for prime time commercial grade production," said Prashant Yadav, a global healthcare supply chain expert at the Center for Global Development in Washington.

Exclusive: WHO-backed vaccine hub for Africa to copy Moderna COVID-19 shot
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Felipe Daniel
Felipe Daniel Sep 14, 2021 1:26PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Vaccines are big business. Neither WHO nor any government cares about your health.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email